Chapter 3. Bacillus Calmette–Guerin (BCG) for Urothelial Carcinoma of the Bladder

  1. Arsénio M. Fialho2 and
  2. Ananda M. Chakrabarty3
  1. Timothy P. Kresowik and
  2. Thomas S. Griffith

Published Online: 18 AUG 2010

DOI: 10.1002/9780470626528.ch3

Emerging Cancer Therapy

Emerging Cancer Therapy

How to Cite

Kresowik, T. P. and Griffith, T. S. (2010) Bacillus Calmette–Guerin (BCG) for Urothelial Carcinoma of the Bladder, in Emerging Cancer Therapy (eds A. M. Fialho and A. M. Chakrabarty), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470626528.ch3

Editor Information

  1. 2

    Institute for Biotechnology and Bioengineering (IBB), Center for Biological and Chemical Engineering, Instituto Superior Tecnico, Lisbon, Portugal

  2. 3

    Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL, USA

Author Information

  1. Department of Urology, University of Iowa, Iowa City, IA, USA

Publication History

  1. Published Online: 18 AUG 2010
  2. Published Print: 16 JUL 2010

ISBN Information

Print ISBN: 9780470444672

Online ISBN: 9780470626528



  • Bacillus Calmette–Guerin (BCG) - for urothelial carcinoma of bladder;
  • BCG development landmarks - immunotherapeutic agents for bladder cancer;
  • genetic determinants of BCG response


This chapter contains sections titled:

  • The Burden of Bladder Cancer and Bacillus Calmette–Guerin (BCG) Immunotherapy

  • Diagnosis of Bladder Cancer

  • Staging of Bladder Cancer

  • Treatment of Urothelial Carcinoma

  • History of M. Bovis BCG

  • Genetic Variability of BCG

  • Clinical use of BCG

  • Bcg Side Effects

  • Bcg Mechanism of Action

  • Neutrophils, Trail, and BCG

  • Genetic Determinants of the BCG Response

  • Genetic Modification of BCG

  • Cellular Component Therapy

  • Combination with Cytokines

  • Conclusion

  • References